Cumulative comorbidity burden does not worsen outcomes in management of chronic rhinosinusitis.
Amarbir S GillJess C MaceRyan RimmerVijay R RamakrishnanDaniel M BeswickZachary M SolerJames ManorRichard R OrlandiTimothy L SmithJeremiah A AltPublished in: International forum of allergy & rhinology (2021)
Although cumulative comorbidity burden, as measured by FCI, is associated with worse baseline SNOT-22 and SF-6D scores, it does not appear to limit posttreatment improvement in either outcome measure. On average, patients with high comorbidity burden report substantial improvement in both QOL and health utility after CRS treatment, similar to those with fewer comorbidities.